# Peptimmune

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/peptimmune

- Industry: Biotechnology
- Headquarters: Cambridge, US
- Total disclosed funding: $79M
- Latest round: Series D (Jul 16, 2008)
- Investors on record: 9

## About

Peptimmune, Inc. is based in US and operates as a clinical stage biotechnology company focused on chronic autoimmune and metabolic disorders.

## Funding rounds

- Series D, Jul 16, 2008, $8.8M — New Enterprise Associates, SVB Capital, Covera Ventures, MPM BioImpact, Boston Medical Investors
- Series D, Jan 18, 2008, $8.2M — New Enterprise Associates, SVB Capital, Covera Ventures, MPM BioImpact, Boston Medical Investors
- Series C, Jul 15, 2005, $20M — New Enterprise Associates, Prism Venture Management, Vanguard Ventures, Covera Ventures, Itochu, MPM BioImpact, Silicon Valley Bank
- Series A, Mar 1, 2003, $41M — New Enterprise Associates, Prism Venture Management, Vanguard Ventures, Covera Ventures, MPM BioImpact, Boston Medical Investors

## Investors

- New Enterprise Associates (https://capitalatlas.ai/funds/new-enterprise-associates) — Series A, Series C, Series D
- Prism Venture Management (https://capitalatlas.ai/funds/prism-venture-management) — Series A, Series C
- Vanguard Ventures (https://capitalatlas.ai/funds/vanguard-ventures) — Series A, Series C
- Covera Ventures (https://capitalatlas.ai/funds/covera-ventures) — Series A, Series C, Series D
- MPM BioImpact (https://capitalatlas.ai/funds/mpm-bioimpact) — Series A, Series C, Series D
- Boston Medical Investors (https://capitalatlas.ai/funds/boston-medical-investors) — Series A, Series D
- Itochu — Series C
- Silicon Valley Bank — Series C
- SVB Capital (https://capitalatlas.ai/funds/svb-capital) — Series D